The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Review article: anti‐adhesion therapies for inflammatory bowel disease
Open accessAbstract
Summary: Background: A high proportion of patients with inflammatory bowel disease (IBD) do not achieve clinical remission with the current therapies including mesalazine (mesalamine), immunossupresants (IMS) and antibodies against tumour necrosis factor (anti‐TNF). Moreover, IMS and anti‐TNF involve a nonnegligible risk for infections and/or malignancies. The anti‐adhesion molecules are one of the most interesting new treatments because of their gut‐selectivity. Aim: To review the physiopathology of the adhesion molecules and the current drugs targeting this mechanism. Methods: We performed a literature review in PubMed and in clinicaltrials.gov using the terms ‘anti‐adhesion molecules’, ‘inflammatory bowel disease’, ‘natalizumab’, ‘vedolizumab’, ‘AMG 181’, ‘Etrolizumab’, ‘PF‐00547659’, ‘AJM 300’, ‘Alicaforsen’ and ‘CCX 282‐B’ up to November 2013. Results: A total of eight drugs were found including those targeting the α4β1, α4β7 or αEβ7 integrins as well as the ICAM‐1 and MA d CAM‐1 addressins and the chemokine receptor 9. The rationale for these drugs is the blockade of gut‐homing T lymphocytes and the ones targeting the α4β7/MA d CAM‐1 interaction presented the most promising results in luminal disease. Vedolizumab, an α4β7 antibody, has completed phase 3 trials with very positive results especially for ulcerative colitis. However, many questions remain unanswered such as the effect of these therapies in perianal disease and extraintestinal manifestations. Conclusions: The blockade of the α4β7/MA d CAM‐1 interaction and especially vedolizumab is an effective and safe gut‐specific treatment for IBD. Further studies are needed to clarify the efficacy and safety of the other anti‐adhesion drugs and to define the specific indications of these therapies in the different scenarios of IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548 · cited 1×
“CS-resistant or CS-dependent disease, in failures to 5-ASA, or in patients achieving remission after induction with ciclosporin.(6) The indications for MTX are similar for UC as for CD, but the evidence is largely lacking, especially for UC.”
BackgroundSelf-citationMechanisms That Regulate the Function of the Selectins and Their Ligands
VESTWEBER, D., & BLANKS, J. E. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.1.181 · Cited by 932
Cited by
A comprehensive review and update on Crohn's disease
Gajendran, M., Loganathan, P., Catinella, A. P., & Hashash, J. G. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2017.07.001 · Cited by 550
ILC3 function as a double-edged sword in inflammatory bowel diseases
Zeng, B., Shi, S., Ashworth, G., Dong, C., Liu, J., & Xing, F. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1540-2 · Cited by 276
Christensen, B., Micic, D., Gibson, P. R., Yarur, A., Bellaguarda, E., Corsello, P., Gaetano, J. N., Kinnucan, J., Rao, V. L., Reddy, S., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14525 · Cited by 91
Metadata
- Authors
- Lobatón, T., Vermeire, S., Van Assche, G., & Rutgeerts, P.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2014-01-30
- Volume
- 39
- Issue
- 6
- Pages
- 579-594
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2009375421
- Cited by
- 165
- References
- 3
- FWCI
- 17.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.